Compare Stocks: AAPG, MAZE, and PGY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$14.55 -2.6%	$16.76	$14.45 ▼ $38.58	$1.40B	0.12	6,308 shs	11,982 shs
MAZE Maze Therapeutics	$25.88 -1.4%	$26.84	$21.95 ▼ $53.65	$1.46B	2.16	936,521 shs	902,994 shs
PGY Pagaya Technologies	$18.26 +0.7%	$20.58	$10.40 ▼ $31.54	$1.51B	5.5	2.60 million shs	1.97 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-2.61%	-8.63%	-16.57%	-27.14%	-63.83%
MAZE Maze Therapeutics	-1.41%	-2.89%	-1.86%	-15.34%	-9.48%
PGY Pagaya Technologies	+0.66%	+4.70%	-17.30%	+1.50%	-39.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$14.55 -2.6%	$16.76	$14.45 ▼ $38.58	$1.40B	0.12	6,308 shs	11,982 shs
MAZE Maze Therapeutics	$25.88 -1.4%	$26.84	$21.95 ▼ $53.65	$1.46B	2.16	936,521 shs	902,994 shs
PGY Pagaya Technologies	$18.26 +0.7%	$20.58	$10.40 ▼ $31.54	$1.51B	5.5	2.60 million shs	1.97 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-2.61%	-8.63%	-16.57%	-27.14%	-63.83%
MAZE Maze Therapeutics	-1.41%	-2.89%	-1.86%	-15.34%	-9.48%
PGY Pagaya Technologies	+0.66%	+4.70%	-17.30%	+1.50%	-39.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.18	Buy	$44.75	207.56% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	144.98% Upside
PGY Pagaya Technologies	3.00	Buy	$31.13	70.45% Upside

Current Analyst Ratings Breakdown

Latest AAPG, MAZE, and PGY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	AAPG Ascentage Pharma Group International	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$46.00 ➝ $33.00
10/6/2026	PGY Pagaya Technologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$26.00 ➝ $25.00
9/28/2026	PGY Pagaya Technologies	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$48.00
9/22/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
9/21/2026	MAZE Maze Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	PGY Pagaya Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
9/3/2026	PGY Pagaya Technologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	16.55	N/A	N/A	$2.04 per share	7.13
MAZE Maze Therapeutics	$167.50M	8.58	N/A	N/A	$7.38 per share	3.51
PGY Pagaya Technologies	$1.30B	1.17	$3.08 per share	5.92	$6.77 per share	2.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	727.50	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
PGY Pagaya Technologies	$81.39M	$1.36	13.43	4.79	N/A	9.12%	51.56%	19.01%	10/29/2026 (Estimated)

Latest AAPG, MAZE, and PGY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	PGY Pagaya Technologies	$0.47	N/A	N/A	N/A	$382.13 million	N/A
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
PGY Pagaya Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
MAZE Maze Therapeutics	0.09	18.31	18.31
PGY Pagaya Technologies	1.12	11.08	11.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
MAZE Maze Therapeutics	N/A
PGY Pagaya Technologies	57.14%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
MAZE Maze Therapeutics	5.30%
PGY Pagaya Technologies	41.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A
PGY Pagaya Technologies	493	83.43 million	48.40 million	Not Optionable

AAPG, MAZE, and PGY Headlines

Recent News About These Companies

Will PGY's Expanding Funding Base Reduce Its Reliance on ABS Markets?

October 8 at 11:01 AM | zacks.com

Pagaya Technologies (NASDAQ:PGY) Stock: Insider Tami Rosen Sells 1,986 Shares

October 7 at 4:52 AM | americanbankingnews.com

Pagaya Announces Timing of Third Quarter 2026 Earnings Release

October 6 at 1:34 PM | marketscreener.comM

Pagaya Technologies (NASDAQ:PGY) Given New $25.00 Price Target at TD Cowen

October 6 at 10:48 AM | americanbankingnews.com

Pagaya Technologies (NASDAQ:PGY) Stock Price Target Cut by TD Cowen

October 6 at 10:47 AM | marketbeat.com

Does Pagaya Technologies’ (PGY) New Funding Facility Subtly Redefine Its Capital-Light Growth Narrative?

October 6 at 8:32 AM | finance.yahoo.com

Pagaya Technologies (NASDAQ:PGY) Director Sells $35,410.38 in Stock

October 6 at 4:52 AM | insidertrades.com

Comparing Dassault Systemes (OTCMKTS:DASTY) and Pagaya Technologies (NASDAQ:PGY)

October 6 at 4:29 AM | americanbankingnews.com

Why Pagaya Technologies Ltd. (PGY) Outpaced the Stock Market Today

October 5, 2026 | zacks.com

Pagaya Technologies (NASDAQ:PGY) Director Tami Rosen Sells 1,986 Shares of Stock

October 5, 2026 | marketbeat.com

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight (PGY)

...

October 5, 2026 | marketbeat.com

PGY Share News Today

October 1, 2026 | uk.investing.com

StoneX Sticks to Their Buy Rating for Pagaya Technologies Ltd (PGY)

October 1, 2026 | theglobeandmail.com

Pagaya Technologies (NASDAQ:PGY) Stock: Insider Sanjiv Das Sells 14,300 Shares

October 1, 2026 | americanbankingnews.com

Pagaya Technologies (NASDAQ:PGY) Stock: Insider Cory Vieira Sells 2,170 Shares

October 1, 2026 | americanbankingnews.com

Pagaya Trades at a Discount: Is the Stock Worth Investing In?

September 30, 2026 | zacks.com

Pagaya Technologies (NASDAQ:PGY) Rating Lowered to Hold at Zacks Research

September 30, 2026 | marketbeat.com

Pagaya Technologies (NASDAQ:PGY) CAO Sells $36,976.80 in Stock

September 30, 2026 | insidertrades.com

Pagaya Technologies Ltd. Secures First Variable Funding Note Facility with ATLAS SP Partners, Advancing Long-Term Committed Capital Strategy

September 29, 2026 | marketscreener.comM

Pagaya Technologies (NASDAQ:PGY) CAO Cory Vieira Sells 2,170 Shares of Company Stock

September 29, 2026 | marketbeat.com

Pagaya Technologies (NASDAQ:PGY) President Sanjiv Das Sells 14,300 Shares of Stock

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AAPG, MAZE, and PGY Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$14.55 -0.39 (-2.61%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$14.64 +0.09 (+0.63%)

As of 04:19 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Maze Therapeutics NASDAQ:MAZE

$25.88 -0.37 (-1.41%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$24.25 -1.63 (-6.29%)

As of 04:09 AM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Pagaya Technologies NASDAQ:PGY

$18.26 +0.12 (+0.66%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$18.26 +0.00 (+0.03%)

As of 04:23 AM Eastern

Pagaya Technologies Ltd., a product-focused technology company, deploys data science and proprietary artificial intelligence-powered technology for financial institutions and investors in the United States, Israel, the Cayman Islands, and internationally. The company develops and implements proprietary artificial intelligence technology and related software solutions to assist partners to originate loans and other assets. Its partners include high-growth financial technology companies, incumbent banks and financial institutions, auto finance providers, and residential real estate service providers. Pagaya Technologies Ltd. was incorporated in 2016 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, MAZE, and PGY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, MAZE, and PGY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, MAZE, and PGY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AAPG, MAZE, and PGY Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Maze Therapeutics NASDAQ:MAZE

Pagaya Technologies NASDAQ:PGY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AAPG, MAZE, and PGY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AAPG, MAZE, and PGY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AAPG, MAZE, and PGY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AAPG, MAZE, and PGY Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Maze Therapeutics NASDAQ:MAZE

Pagaya Technologies NASDAQ:PGY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools